Story · Medicine & Biotech
GLP-1s now carry a warning about a rare vision-threatening eye condition
3 outlets · first reported by UC Davis Health News on · latest · 57 hours of coverage · 2 countries
On Nov. 9, the U.S. Food and Drug Administration (FDA) announced it will require manufacturers of GLP-1 medications, including Ozempic, Wegovy, Mounjaro and Zepbound, to add a warning about a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). An eye expert explains… (UC Davis Health News)
Coverage, in order
-
GLP-1s now carry a warning about a rare vision-threatening eye condition
On Nov. 9, the U.S. Food and Drug Administration (FDA) announced it will require manufacturers of GLP-1 medications, including Ozempic, Wegovy, Mounjaro and Zepbound, to add a warning about a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). An eye expert explains…
-
GLP-1s: FDA issues warning over rare eye condition
A new warning on all GLP-1 agonists over a rare eye condition that could cause sudden, permanent blindness, has been issued by US regulators.Following an investigation, the US Food and Drug Administration (FDA) announced that it would now require all manufacturers of GLP-1 drugs, such as Ozempic…
-
A Physician Explains GLP-1s’ Biggest Potential Side Effect: A Rare But Serious Eye ConditionWhat is the risk for the millions of people worldwide who take GLP-1 medications?
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.